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Abstract: Sebaceous tumours and keratoacanthomas are 
uncommon neoplasms that constitute important clinical 
criteria for Muir-Torre syndrome (MTS) diagnosis. In MTS 
patients, the increased risk of developing synchronous 
or metachronous visceral malignancies is characterised 
by autosomal dominant inheritance. However, there are 
further conditions, other than MTS, that increase the risk 
of sebaceous neoplasms, e.g. iatrogenic immunosuppres-
sion. In this latter scenario, the sebaceous tumours can 
present microsatellite instability (MSI) and loss of mis-
match repair (MMR) proteins, characteristic of hereditary 
syndromes, even in the absence of MMR germline muta-
tions. In this article, we examine transplant probands in 
which the immunosuppressive therapies unmask the MTS 
cutaneous phenotypes, showing MSI and loss of MMR 
protein expression, as demonstrated by immunohisto-
chemistry (IHC). Furthermore, MMR genes sequencing 
analysis identified the presence of germline mutations in 
MTS-suspected individuals, in the absence of a visceral 
MTS phenotype. It is well known that immunosuppres-
sion plays a central role in the development of sebaceous 
tumours in both MTS and in non-syndromic settings. 
Sebaceous skin tumours’ MSI status and IHC profiles can 
be influenced by epigenetic or iatrogenic factors; how-
ever, they constitute valuable tools and a cost-effective 
approach to screen individuals who otherways should 
undergo MMR genes direct sequencing in the context of 
immunosuppression. In this complex setting, the choice 
of the immunosuppressive drug becomes a critical deci-
sion for the management of both MTS and sporadic trans-
plant patients, which may benefit from the administration 
of immunosuppressive drugs, resulting in a low impact on 
skin cancerogenesis.
Keywords: immunohistochemistry; immunosuppressed 
transplant patients; microsatellite instability; mis-
match repair germline aberrations; Muir-Torre syndrome 
phenocopy.
Introduction
Immunosuppressed organ transplant recipients have an 
increased risk of malignancies [1]. Generally, the non-
melanoma skin cancers (NMSCs) are the most frequently 
reported tumours affecting this population; in fact, cohort 
studies of recipients of organ transplants demonstrate 
a 50- to 100-fold increased risk of squamous cell car-
cinoma (SCC) and a 5- to 10-fold increased risk of basal 
cell carcinoma (BCC) compared with the general popu-
lation [2]. It has been demonstrated that the cumulative 
risk of NMSC in transplant recipients may be as high as 
40% by 20 years after transplantation [1]. Among NMSCs, 
evidence of an increased incidence of sebaceous tumours 
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arises in transplant recipients [3–5], even though the seba-
ceous appendageal tumours are uncommon, difficult to 
diagnose before excision and pathological analysis, and 
usually associated to hereditary cancer syndromes [6–8]. 
In fact, the presence of early-onset sebaceous tumours and 
keratoacanthomas associated to visceral malignancies is 
distinctive of the so-called Muir-Torre syndrome (MTS), a 
variant of Lynch syndrome (LS) [9, 10]. MTS or LS asso-
ciated tumours are featured by the presence of a typical 
microsatellite loci instability (MSI), which is caused by 
mismatch repair (MMR) germline mutations responsible 
of the loss of MMR protein expression, as evidenced by 
immunohistochemistry (IHC) analysis [11–13].
Although detailed reports of appendageal tumours 
have been reported developing in the context of trans-
plant-related primary immunosuppression [1, 14–16], 
this clinical-pathologic relationship has not been fully 
explained. The literature reports that sebaceous tumours 
and keratoacanthomas occurring during immunosup-
pression show MSI and loss of IHC expression of MMR 
proteins, even in the absence of documented MMR ger-
mline mutations [17,  18]. Along the same lines, it is also 
known that the occurrence of sebaceous tumours is mod-
ulated by specific type of immunosuppressive drugs [19, 
20], and some primary and secondary immunodepres-
sive conditions are associated to an increased incidence 
of rare sebaceous tumours [21], showing MSI and IHC 
aberrations. In this regard, beyond the direct pathogenic 
effect of oncogenic viruses [13], a role for immunosup-
pressive therapies [18, 22–24], genetic aberrations [22, 25] 
and MLH1 hypermethylation [26] have been hypothesised. 
Regarding this latter phenomenon, it is known that some 
MSI-high cancers are due to aberrant MLH1 gene promoter 
methylation, a somatic event leading to LS/MTS pheno-
copies [26, 27]. Interestingly, recent in vitro evidence show 
that some immunosuppressive drugs (i.e. tacrolimus) can 
condition the DNA methylation status inducing specific 
epigenetic modifications, in particular hypermethylation, 
of some genes [28]; these preliminary laboratory evidence 
shed some light on the intriguing relationship between 
immunosuppression and hypermethylation.
In this article, we have reviewed the literature with 
the aim to explain the clinical history of patients with 
numerous familial visceral malignancies, experiencing 
the onset of several sebaceous adenomas after receiving 
immunosuppressive therapy with tacrolimus (Prograf©), 
administered to prevent kidney transplant rejection.
Cyclosporin A (CsA) and tacrolimus are the most com-
monly used immunosuppressive drugs to prevent rejec-
tion in transplant patients. Tacrolimus is the generic 
name for the macrolide immunosuppressant previously 
known as FK506 [29] and is produced by Streptomyces 
tsukabaensis, a bacterium found in the soil near Tsukuba, 
Japan. The mechanism of action of tacrolimus is closely 
related to that of cyclosporine. However, while tacrolimus 
binds tightly to the cellular protein named FK506-binding 
protein 12 (FKBP12), cyclosporine binds cyclophilin. The 
target of either drugs or intracellular receptor complex is 
a calcium-activated phosphatase, calcineurin, required 
for many functions in a variety of tissues. The immune 
response suppression leads to therapeutic efficacy in 
transplantation, but it also leads to an increased risk 
of tumours [1]. In addition to the immunosuppressive 
activity, tacrolimus affects tumour development and 
growth via different molecular mechanisms, such as the 
over-expression of VEGF-C, inhibiting apoptosis in non- 
lymphoid tissues and influencing crucial cancer signal-
ling pathways (e.g. Erk and p53) [30, 31].
The impact of immunosuppres-
sion on MMR genes deficiency and 
sebaceous carcinogenesis: our 
clinical and laboratory experience
Our experience is based on the retrospective assessment 
of a cohort of immunosuppressed transplant patients that 
assumed anti-rejection therapies and developed multiple 
eruptive sebaceous neoplasms and keratoacanthomas. 
The lesions always occurred suddenly as firm, fast 
growing, flesh coloured papules and nodules of the face 
and had translucent, telangiectasia-like surface, often 
associated with central erosion/ulceration [32]. The main 
clinical and dermoscopic differential diagnosis included 
other sebaceous tumours, BCC, adnexal tumours and 
keratoacanthomas [32]. The skin neoplasms were surgi-
cally excised and the pathologist observed well defined, 
enlarged, sebaceous lobules with fully mature sebocytes, 
frequently demonstrating an attachment to the epidermis 
with epidermal thinning, as it occurs in sebaceous ade-
nomas. A detailed family history was collected for each 
patient by conducting interviews of the patients and/or 
of their relatives. Verification of cancer occurrence among 
family members was obtained in the majority of patients 
through clinical and pathological records, or death certifi-
cates. Our approach was based on the assessment of bio-
molecular (MSI) and IHC characteristics of the sebaceous 
neoplasms, leading to the identification of a high MSI and 
a loss of expression of the MMR proteins (IHC) in sebaceous 
tumour and KA excised from the immunosuppressed 
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patient even in the absence of visceral neoplasm and clear 
MTS clinical diagnosis (Figure 1).
In this clinical scenario, it is important to pursue 
the concept that immunosuppressed patients with mul-
tiple sebaceous neoplasms and keratoacanthomas are 
often affected by MTS; therefore, the clinician has a clear 
indication to perform endoscopy in order to screen these 
patients, for an increased risk of visceral neoplasms [22, 
25]. For the molecular diagnostic confirmation of MTS, 
taking into account the high concordance, near to 100%, 
between MSI and IHC, whenever one of these two tests 
result in changes compatible with MTS, the presence of 
germline mutations should also be investigated by the 
direct sequencing of MMR genes, when at least one of the 
preliminary molecular and/or IHC tests is suggestive of a 
hereditary setting.
Even though it is known that immunosuppression 
is a risk factor for sebaceous tumours, it is our opinion 
that whenever an immunosuppressed patient is affected 
by sudden multiple sebaceous lesions erupted at a rela-
tively young age, with positive MSI and IHC, the clinician 
should perform the MMR genetic sequencing. Therefore, 
we suggest as a practical workflow for the management 
of these patients that MSI and IHC should be determined 
first, and only if they are positive, direct genetic sequenc-
ing of MMR genes should be performed in order to deter-
mine if the patient is affected by MTS.
Some of the patients in our cohort are emblematic 
of the clinical condition aforementioned, e.g. RTR1 was 
diagnosed a colonic adenoma at the age of 36. He under-
went renal transplant at the age of 49 because of an end-
stage renal failure after glomerulonephritis initiating at 
the age of 35. After the transplant, he developed a BCC on 
the nose and a keratoacanthoma on the face. At the age 
of 52, he developed five sebaceous adenomas, four located 
on the face and one in the lumbar region. All sebaceous 
Figure 1: Histological and IHC analysis of a sebaceous adenoma of RTR.
The histological analysis of one of the nodules of the face of RTR1 showed a well-demarcated intradermal mass characterised by discrete 
lobules formed by a variable number of sebocytes and basaloid cells not arranged around a distended duct, as is found with sebaceous 
hyperplasia (haematoxylin and eosin stain) (A, B). IHC of the same tumour showing absence of MSH2 protein (C) and presence of MLH1 
product (D).
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tumours were adenomas and shared the same molecu-
lar markers, IHC MMR protein expression, mutation and 
methylation. The systemic genetic analysis performed on 
leukocyte blood cells revealed the presence of a germline 
MSH2 mutation at codon 406, c.1216C > T (p.Arg406x) cor-
responding to a stop codon with consequent loss of func-
tion of MSH2. Among his relatives, his sister had a positive 
personal history of colon cancer discovered at the age of 
65, while another sister and a niece were diagnosed with 
endometrial cancer at the age of 54 and 50, respectively. 
The patient was under immunosuppressive treatment with 
prednisone and tacrolimus (Figure 1). However, cutaneous 
sebaceous tumours did not affect his family members.
Another patient, RTR2, underwent kidney trans-
plant in 1998 at the age of 45 and developed a sebaceous 
adenoma of the left lower eyelid at the age of 58. Later on, 
two more sebaceous adenomas of the face were found. 
The patient has not been diagnosed of any visceral malig-
nancies so far and he is affected by Berger syndrome. The 
systemic genetic analysis performed on leukocyte blood 
cells revealed the presence of a germline MSH6 mutation 
at codon 782, c.2345T > C (p.Leu728Pro) that generates 
a variant of uncertain significance (Class III) [26]. In his 
family, two sisters had uterine fibromas and one of them 
also had colon cancer of the sigmoid tract with liver metas-
tasis; moreover, one maternal uncle had colon cancer. The 
patient was under immunosuppressive treatment with 
CsA and switched to prednisone and tacrolimus in 2012.
The role of immunosuppressive 
therapy
Sebaceous tumours are rare, but they are the most common 
cutaneous appendage tumours in the immunosuppressed 
transplant recipients [18]. The occurrence of sebaceous 
tumours was previously related to the iatrogenic immuno-
suppressive therapies [14–16], to the infection with human 
immunodeficiency virus [33], to the development of Hodg-
kin’s lymphoma [34] and to the presence of MMR germline 
mutations in the setting of MTS/HNPCC spectrum [6].
While an inherited MMR defect can always be sus-
pected in the majority of patients with sebaceous gland 
tumours, it is important to investigate the molecular mech-
anism underlying the development of these neoplasms in 
the transplant recipients and their clinical implications in 
the MTS patients’ screening.
Regarding the iatrogenic factors, azathioprine has 
been postulated to contribute to the selection of cells 
bearing DNA MMR deficits, evading its cytotoxic effects 
[35]: in fact, there is evidence suggesting that immuno-
suppressive drugs, most plausibly azathioprine, could 
determine the selection of a mutator phenotype predis-
posing to the development of sebaceous neoplasms [21]. 
Cyclosporine and tacrolimus are calcineurin inhibitors 
and have been hypothesised to increase tumour growth 
through the increase of transforming growth factor 
(TGF)-β and interleukin-6 [24, 36]. Maluccio et  al. found 
that tacrolimus has a dose-dependent effect on tumour 
progression and TGF-β1 expression in mice [37]. TGF-β1 
is a multifunctional cytokine related to tumour invasive-
ness and metastatic progression. In addition, tacrolimus 
may affect tumour growth and development by the over-
expression of VEGF-C as it was demonstrated in tacrolimus 
treated hepatocellular carcinoma-bearing rat. The main 
target of VEGF is the endothelial cell, where it modulates 
the angiogenesis and/or lymphangiogenesis mechanism, 
but it also exerts other effects upon the differentiation 
and pathophysiology of different cell types including 
the sebocytes [38]. Several studies have demonstrated 
the presence of VEGFRs in liquid and solid tumour cells, 
such as NSCLC, melanoma, prostate cancer, leukaemia, 
mesothelioma and breast cancer [39], being involved in 
microvascular permeability, endothelial cell proliferation, 
migration and invasion [40]. It should be further noted 
that despite an increase of apoptosis in T-cells, tacrolimus 
was also shown to inhibit apoptosis in non-lymphoid cells 
[31, 41]. Moreover, an influence on proteins of some of the 
most significant cancer signalling pathways (e.g. Erk and 
p53) has been demonstrated [31]. Consequently, the carci-
nogenic potential of tacrolimus may be also due to a direct 
effect, promoting the transformation of initiated cells. A 
direct link between tacrolimus and Bcl-2 family proteins 
should also be taken into consideration: the tacrolimus-
binding protein FKBP38 blocks apoptosis, binds to Bcl-2 
and targets Bcl-2 in mitochondria [41].
It has been reported that the switching from tacroli-
mus to sirolimus halts the appearance of new sebaceous 
neoplasms in MTS patients [19]. Sirolimus was initially 
discovered as an antifungal metabolite produced by 
Streptomyces hygroscopicus, it forms a gain-of-function 
complex with the FKBP12; this complex acts as an inhibi-
tor of mammalian TOR (mTOR) complex 1 (mTORC1) [42]. 
Constitutive hyperactive mTORC1 signalling is directly 
linked to the unregulated cell growth that drives the clini-
cal manifestations of lymphangioleiomyomatosis (LAM) 
and tuberous sclerosis (TSC), which is characterised by 
the development of benign hamartomatous tumours 
involving multiple organs. Both LAM and TSC are caused 
by loss-of-function mutations in the TSC genes (TSC1 or 
TSC2), whose protein products function as a complex to 
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inhibit the activity of mTORC1. Sirolimus and rapamycin 
analogues possess immunosuppressive and antiprolif-
erative properties in mammalian cells, impairing cancer 
metabolism, suppressing protein synthesis and inducing 
autophagy. Thus, drugs that selectively target mTORC1, 
like rapamycin, are expected to impair cancer metabolism 
and are considered a promising anticancer therapy [42].
In our renal transplant patients (RTR1 and RTR2), the 
occurrence of sebaceous adenomas during the tacroli-
mus-based immunosuppressive regimens represented 
the leading event to investigate MSI and MMR IHC protein 
status and to analyse the sequence of the MMR genes 
unveiling, respectively, MSH2 and MSH6 germline altera-
tions, compatible with MTS diagnosis (Figure 2). As con-
firmed by the genetic alterations in MSH6 gene found in 
RTR2, it was possible to pose the MTS diagnosis even in 
the absence of visceral malignancies or the fulfilling of 
MTS clinical criteria. This evidence has important clini-
cal implications in the management of MTS-suspected 
patients showing cutaneous MTS stigmata only, which 
should be screened for MTS visceral tumour spectrum.
The assessment of MSI and MMR through IHC analysis 
in a sebaceous gland neoplasm is highly relevant for the 
detection of familial cancer predisposition. However, it is 
known that sebaceous tumours and KA can display MSI 
and loss of MMR protein expression even in the absence 
of MMR germline mutations. The reason underlying this 
phenomenon is not completely understood; some authors 
suggested that the mechanisms of development of MSI in 
sporadic colonic and endometrial carcinomas and also in 
sebaceous neoplasms [43] are related to the biallelic inac-
tivation of the hMLH-1 gene either by mutation or by pro-
moter hypermethylation [26, 27, 44].
The high incidence of MSI and the lack of MMR protein 
expression in sebaceous tumours and KA from RTR 
suggest either that immunosuppression unmasks a latent 
MTS phenotype or an interaction between MMR proteins 
and immunosuppressive drugs eliciting in immune sur-
veillance diminution and, in some cases, exerting a carci-
nogenic effect associated to MSI and loss of MMR proteins.
The MTS-suspected population could include both 
the patients harbouring the sebaceous tumours or ker-
atoacanthomas in the absence of visceral neoplasm phe-
notype, and the immunosuppressed patients, presenting 
sebaceous gland tumours with MSI and loss of MMR pro-
teins, as evidenced by IHC. In the first case, MMR genes 
sequencing should be performed in order to define the 
molecular diagnosis of MTS; concerning the latter, even 
though the incidence of sebaceous tumours in the immu-
nosuppressed patient is possible, it is important to remem-
ber that immunosuppression may “unmask” a MMR gene 
defect that has to be investigated through direct gene 
sequencing.
The identification of immunosuppressed patients 
with MMR gene mutations, therefore affected by MTS, is 
of great relevance, prompting to perform a screening for 
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Figure 2: Electropherograms of RTR1 MSH2 showing the mutation c.1216C > T p.Arg406 (A), and of RTR2 MSH6 showing the variant of 
unknown significance c.2345T > C p.Leu728Pro (B), as indicated by arrows.
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MTS visceral tumours and a genetic screening addressed 
to the first- and second-degree relatives of the patients.
In conclusion, although rare sebaceous tumours and 
keratoacanthomas constitute the clinical criteria for the 
diagnosis of MTS, the same tumours can also be found 
within an immunosuppressive context.
The combination of MSI and IHC status can therefore 
be considered essential for MTS detection, even in case 
of an incomplete MTS phenotype and/or in immunosup-
pressed patients, allowing a cost-effective approach in 
the screening of individuals who are meant to undergo 
MMR genes direct sequencing. Given the aforemen-
tioned molecular and clinical evidence, the administra-
tion of some immunosuppressive drugs to MTS patients 
and to immunosuppressed MTS-suspected patients may 
have a crucial impact on the cutaneous expressivity of 
the MTS phenotype. Therefore, the immunosuppressive 
drug choice should be done taking into consideration 
that some immunomodulatory molecules (i.e. sirolimus) 
are able to prevent sebaceous carcinogenesis because of 
the mechanism of action, an important advantage for the 
patient that has to be considered whenever starting a life-
long immunosuppressive therapy. The best therapeutic 
choice for MTS patients, both with partial or complete 
phenotypic expression, needs further study to compare 
the benefits and side effects that can be attained by adopt-
ing different immunosuppressive agents.
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